Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)

Terapevticheskii Arkhiv

Volumn 77, Issue 8, 2005, Pages 34-43

  Skvortsov, A A ^a   Nasonova, S N ^a   Sychev, A V ^a   Arbolishvili, G N ^a   Baklanova, N A ^a   Mareev, V Yu ^a   Belenkov, Yu N ^a  

^a NONE

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Chronic cardiac failure; Heart rate variability; Treatment

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; NORADRENALIN; QUINAPRIL; RENIN; TETRAHYDROISOQUINOLINE DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMAN; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; RENIN; TETRAHYDROISOQUINOLINES; TETRAZOLES; VALINE;

EID: 25444506391     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Grossi G., Seravalle G., Cattaneo B. M. et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995; 92: 3206-3211.
2. Francis G. S., Benedict C., Johnstone D. E. et al. Comparison of neuroendocrine activation in patients with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724.
3. Swedberg K., Eneroth P., Kjekshus J., Wilhelmen L. for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-1736.
4. Nolan J., Batin P. D., Andrews R. et al. Prospective study of heart rate variability and mortality in chronic heart failure. Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-Heart). Circulation 1998; 98: 1510-1516.
5. Bilchick K. C., Fetis B., Djoukend R. et al. Prognostic value of heart rate variability in chronic congestive heart failure (veterans affairs' survival trial of antiarrhythmic therapy in congestive heart failure). Am. J. Cardiol. 2002; 90: 24-28.
6. Goldsmith S. R. Angiotensin II and sympathoactivation in heart failure. J. Card. Fail. 1999; 5: 139-145.
7. Averill D. B., Diz D. I. Angiotensin peptides and baroreflex control of sympathetic outflow: pathways and mechanisms of the medulla oblongata. Brain Res. Bull. 2000; 51: 119-128.
8. DiBona G. F. Central sympathoexcitatory actions of angiotensin II: role of type 1 angiotensin II receptors. J. Am. Soc. Nephrol. 1999; 10 (suppl. 11): S90-S94.
9. Yee K. M., Struthers A. D. Aldosterone blunts the baroreflex response in man. Clin. Sci. 1998; 95: 687-692.
10. Witherow F. N., Helmy A., Webb D. J. et al. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation 2001; 104: 2177-2181.
11. Grassi G., Cattaneo B. M., Seravalle G. et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997; 96: 1173-1179.
12. Jorde U. P., Ennezat P. V., Lisker J. et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000; 101: 844-846.
13. Urata H., Healy B. H., Stewart R. et al. Angiotensin II forming pathways in normal and failing human hearts. Circ. Res. 1990; 66: 883-890.
14. McKelvie R. S., Yusuf S., Pericak D. et al. Comparison of can- desartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation 1999; 100: 1056-1064.
15. Willenheimer R., Helmers C., Pantev E. et al. for the Heart Failure Valsartan Exercise capacity Evaluation (HEAVEN) Study Group. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int. J. Cardiol. 2002; 85: 261-270.
16. Vaile J. C., Chowdhary S., Osman F. et al. Effects of angiotensin II (ATI) receptor blocade on cardiac vagal control in heart failure. Clin. Sci. 2001: 101: 559-566.
17. De Tommasi E., Iacoviello M., Romito R. et al. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. Am. Heart J. 2003; 146: e17.
18. Packer M. The neurohormonal hypothesis. A theory explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol. 1992; 20: 248.
19. Dzau V. J., Hirch A. T. Emerging role of the tissue renin-angiotensin systems in congestive heart failure. Eur. Heart J. 1990; 11: 65-71.
20. Dzau V. J. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Basic Res. Cardiol. 1993; 88: 1-14.
21. Lee A. F. C., MacFadyen R. J., Struthers A. D. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur. J. Heart Fail. 1999; 1: 401-406.
22. Jansson K., Dahlstrom U., Karlberg B. E. et al. The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy. J. Intern. Med. 1999; 245 (5): 435-443.
23. Sigurdsson A., Swedberg K., Ullman B. Effects of ramipril on the neurohormonal response to exercise in patients with mild to moderate congestive heart failure. Eur. Heart J. 1994; 15: 247-254.
24. Serneri G. G. N., Boddi M., Cecioni I. et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ. Res. 2001; 88: 961-968.
25. Petrie M. C., Padmanabhan N., McDonald J. E. et al. Angiotensin- converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J. Am. Coll. Cardiol. 2001; 37: 1056-1061.
26. Brunner-La Rocca H. P., Weilenmann D., Kiowski W. et al. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am. Heart J. 1999; 138 (4): 654-662.
27. van Veldhuisen D. J., Genth-Zotz S., Brouwer J. et al. High-versus low-dose ACE inhibition in chronic heart failure. A double-blind, placebo-controlled study of imidapril. J. Am. Coll. Cardiol. 1998; 32: 1811-1818.
28. Farguharson C. A., Struthers A. D. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J. Am. Coll. Cardiol. 2002; 39: 767-775.
29. Packer M., Poole-Wilson P. A., Armstrong P. W. et al. on behalf of the ATLAS study group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999; 100: 2312-2318.
30. McMurray J. J. V., Ostergren J., Swedberg K. et al. for the CHARM investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function talcing angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 2003; 362: 767-771.
31. Cohn J. N., Tognoni G. for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 2001; 345: 1667-1675.
32. Staessen J., Lijnen P., Fagard P. et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J. Endocrinol. 1981; 91: 457-465.
33. Borghi C., Boschi S., Ambrosioni E. et al. Evidence of a partial escape of renin-angiotensine-aldosterone blocade in patients with acute myocardial infarction treated with ACE inhibitors. J. Clin. Pharmacol. 1993; 33: 40-45.
34. Xiu J. C., Wu P., Xu J. P. et al. Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone. J. Endocrinol. Invest. 2002; 25: 463-468.
35. Riegger G. A. J., Bouzo H., Petr P. et al. for the Symptoms, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Circulation 1999; 100: 2224-2230.
36. Cohn J. N., Anand I. S., Latini R. et al. for the Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure. Results from Valsartan Heart Failure Trial. Circulation 2003; 108: 1306-1309.
37. Skvortsov A. A., Mareev V. Yu., Naumov V. G., Belenkov Yu. N. Interactions between renin-angiotensin-aldosterone system and atrial natriuretic peptide in patients with congestive heart failure. Results with acute test with captopril. In: Second International symposium on ACE inhibition, 17-21 Feb., 1991, London. London; 1991. abstr. P-52.
38. Houghton A. R., Harrison M., Cowley A. J. Haemodynamic, neurohumoral and exercise effects losartan vs. captopril in chronic heart failure: results of an ELITE trial substudy. Eur. J. Heart Fail. 1999; 1: 385-393.
39. Christensen G., Aksnes G., Ilebekk A., Kill F. Realese of atrial natriuretic factor during selective α- and β-adrenergic stimulation, intracoronary Ca infusion and aortic constriction in pigs. Circ. Res. 1991; 68: 638-644.
40. Latini R., Masson S., Anand I. et al. for the Val-HeFT Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. Circulation 2002; 106: 2454-2458.
41. Antonaccio M. J., Kerwin L. Pre- and postjunctional inhibition of vascular sympathetic function by captopril in SHR: implication of vascular angiotensin-II in hypertension and antihypertensive actions of captopril. Hypertension 1981; 3 (suppl. 1): I-54-I-62.
42. Eriksson S. V., Eneroth P., Kjekshus J. et al. Neuroendocrine activation in relation to left ventricular function in chronic severe congestive heart failure: a subgroup analysis from the Cooperative North Scandinavisn Enalapril Survival Study (CONSENSUS). Clin. Cardiol. 1994; 17 (11): 603-606.
43. Rundqvist B., Eisenhofer G., Elam M., Friberg P. Attenuated cardiac sympathetic responsiveness during dynamic exercise in patients with heart failure. Circulation 1997; 95: 940-945.
44. Zhu G.-Q., Patel K. P., Zucker I. H., Wang W. Microinjection of ANG II into paraventricular nucleus enhances cardiac sympathetic afferent reflex in rats. Am. J. Physiol. Heart Circ. Physiol. 2002; 282: H2039-H2045.
45. Liu J. L., Zucker I. H. Regulation of sympathetic nerve activity in heart failure. A role for nitric oxide and angiotensin II. Circ. Res. 1999; 84: 417-423.
46. Campese V. M., Ye S., Zhong H. Downregulation of neuronal nitric oxide synthase and interleukin-1β mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension 2002; 39 (2): 519-524.
47. Mitrovic V., Willenbrock R., Miric M. et al. on behalf of the study investigators. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. Am. Heart J. 2003; 145: e14.
48. Houghton A. R., Harrison M., Cowley A. G., Hampton J. R. Combined treatment with losartan and an ACE inhibitor in mild to moderate heart failure: results of double-blind, randomized, placebo-controlled trial. Am. Heart J. 2000; 140: 791-797.
49. Brunner-La Rocca H. P., Esler M. D., Jennings G. L., Kaye D. M. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur. Heart J. 2001; 22: 1136-1143.
50. Tygesen H., Rundquist B., Waagstein F., Wennerblom B. Heart rate variability measurement correlates with cardiac norepinephrine spillover in congestive heart failure. Am. J. Cardiol. 2001; 87: 1308-1311.
51. Thomas G. P., Ferrier G. R., Howlett S. E. Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in stimulated ventricular ischemia and reperfussion. J. Pharmacol. Exp. Ther. 1996; 278: 1090-1097.
52. Townend J. N., West J. N., Davies M., Littler W. A. Effect of quinapril on blood pressure and heart rate in congestive heart failure. Am. J. Cardiol. 1992; 69: 1587-1590.
53. Zhang Y., Sang Y., Zhu J. Effects of enalapril on heart rate variability in patients with congestive heart failure. Am. J. Cardiol. 1995; 76: 1045-1048.
54. Murakami H., Liu J. L., Zucker I. H. Blockade of ATI receptors enhances baroreflex control of heart rate in conscious rabbits with heart failure. Am. J. Physiol. 1996; 271: R303-R309.
55. Heusser K., Vitkovsky J., Schmieder R. E., Schobel H. P. ATI antagonism by eprosartan lowers heart rate variability and baroreflex gain. Auton. Neurosci. 2003; 107: 45-51.